Solubilized Proteins from Carrot

Total Page:16

File Type:pdf, Size:1020Kb

Solubilized Proteins from Carrot Proc. Nati. Acad. Sci. USA Vol. 90, pp. 765-769, January 1993 Plant Biology Solubilized proteins from carrot (Daucus carota L.) membranes bind calcium channel blockers and form calcium-permeable ion channels (voltage-dependent Ca2+ channel/signal transduction/cytosofic caldum/plant ion channel/liposome) PATRICE THULEAU*t, ANNICK GRAZIANA*, RAOUL RANJEVAf, AND JULIAN I. SCHROEDER* *Department of Biology and Center for Molecular Genetics, University of California, San Diego, La Jolla, CA 92093-0116 and *Centre de Biologie et Physiologie Vdgdtales, Universitd Paul Sabatier, Centre National de la Recherche Scientifique, 118 Route de Narbonne, F-31062 Toulouse Cddex, France Communicated by Bernard 0. Phinney, September 28, 1992 (receivedfor review January 1, 1992) ABSTRACT Calcium channels have been suggested to play A plasma membrane protein of75-kDa molecular mass that a major role in the initiation of a large number of signal binds with high affinity to a phenylalkylamine azido deriva- transduction processes in higher plant cells. However, molec- tive, (-)-5-(3-azidophenylethyl[3H]methylamino)-2-(3,4,5- ular components of higher plant Ca2+ channels remain uni- trimethoxyphenyl)-2-isopropylvaleronitrile ([3H]LU 49888), dentified to date. Calcium channel blockers of the phenylal- has been identified in carrot cells (13). This protein retains its kylamine family and bepridil specifically inhibit Ca2+ influx ability to bind Ca2+ channel antagonists upon solubilization into carrot (Daucus carota L.) cells. By using a phenylalky- by a nondenaturating detergent, 3-[(3-cholamidopropyl)di- lamine azido derivative, a 75-kDa carrot membrane protein methylammonio]-l-propanesulfonate (CHAPS) (13). In the had been previously identified. Here we have partially purified present study, we investigated, using reconstitution experi- this Ca2+ channel blocker-binding protein by lectin-affinity ments and the patch-clamp technique, whether membrane and ion-exchange chromatographies. The protein fraction con- protein fractions enriched with the 75-kDa binding protein taining the 75-kDa binding protein was incorporated into gat from carrot cells contribute to Ca2+-permeable ion channel liposomes. Single-channel patch-clamp studies on these prote- function and sensitivity to Ca2+ channel blockers. This oliposomes showed the presence of Ca2+-permeable channel approach allows biochemical insight into components con- currents. These Ca2+-permeable channels were not stable. tributing to the structure of Ca2+ channels of higher plants. Recordings after durations of2-10 min showed the appearance of nonselective ion channels with a permeability to calcium and MATERIALS AND METHODS chloride ions. These nonselective Ca2+-permeable ion chan- nels, in contrast, were stable and were recorded for extended Plant Material, Membrane Preparation, and Storage. Sus- durations. The addition of the Ca2+ channel-blocker bepridil pension cultures of carrot (Daucus carota L.) cells were (10 FM) led to the inhibition of these nonselective Ca2+- prepared as described previously (11). Total membranes permeable channels by reducing the probability of channel were prepared according to a published procedure (11). opening. These results suggest that the 75-kDa Ca2+ channel Membranes were used directly after preparation or after blocker-binding protein from carrot cells plays a role in storage at -80'C. Protein concentrations were measured by channel sensitivity to Ca2+ channel inhibitors and may consti- the bicinchoninic acid assay (15). tute one of the components of Ca2+ channels in higher plants. Photolabeling. The presence of the calcium channel blocker-binding protein was verified by photoaffinity labeling A signal-induced increase in the cytosolic Ca2+ concentration with [3H]LU 49888 as described previously (13). The non- is considered to be among the most important intracellular specific component of the binding was determined in the messengers for initiation of metabolic and developmental presence of the unlabeled calcium channel blocker (-)- events in higher plants. Calcium controls various processes, bepridil at 50 ,.M. The photolabeled microsomes were used including cellular organization, ion channel gating and en- as starting material to purify the [3H]LU 49888-binding zyme activities, during physiological responses to external protein complex. Bepridil was from Laboratoire Cerm stimuli (1-5). The influx of calcium into the cytosol of plant (Riom, France), and [3H]LU 49888 (3.15 TBq/mmol) was cells is mediated by Ca2+-permeable signal-regulated ion from Knoll (Ludwigshafen, F.R.G.). channels which traverse the plasma membrane and vacuolar Solubilization and Purification of the Calcium Channel membrane (refs. 6 and 7; for reviews, see refs. 8 and 9). Blocker-Binding Protein. Membrane proteins were solubi- In spite of the demonstration that Ca2+ influx systems are lized as described (13). The solubilized proteins were diluted involved in physiological processes in plants, the molecular 10-fold with 20 mM Tris HCl, pH 7.5/5% (vol/vol) glycerol structure of Ca2+ channel components remains unidentified and loaded onto a concanavalin A (Con A)-Sepharose column in higher plant cells. Pharmacological agents, referred to as (Pharmacia LKB) equilibrated in 20 mM Tris HCl, pH Ca2+ channel blockers or antagonists, are known to interfere 7.5/5% glycerol/0.1% CHAPS (buffer A). The column was with a variety of plant functions (1, 4, 9). High-affinity washed with buffer A and the calcium channel blocker- membrane for these have been char- binding protein was eluted with 0.25 M methyl a-D- receptors compounds mannopyranoside in buffer A and loaded onto a DEAE- acterized in different plants (10-13). Site occupancy of these trisacryl column (IBF) equilibrated in buffer A. Unbound receptors results in the inhibition of Ca2+ uptake into carrot materials were washed with 100 mM NaCl in buffer A, and protoplasts (11, 14). The most potent antagonists of Ca2+ the retained the ion were eluted a influx found to date for higher plants are phenylalkylamines proteins by exchanger by and bepridil (11, 14). Abbreviation: CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]- 1-propanesulfonate. The publication costs of this article were defrayed in part by page charge tPresent address: Centre de Biologie et Physiologie Vdgdtales, payment. This article must therefore be hereby marked "advertisement" Universitt Paul Sabatier, Centre National de la Recherche Scien- in accordance with 18 U.S.C. §1734 solely to indicate this fact. tifique, F-31062 Toulouse CUdex, France. 765 Downloaded by guest on September 28, 2021 766 Plant Biology: Thuleau et al. Proc. Natl. Acad Sci. USA 90 (1993) gradient 100-300 mM NaCl in buffer A. The fractions con- interval of 100 ,usec, and analyzed by using the program taining the binding protein (eluted at 200 mM NaCl) were PCLAMP (Axon Instruments). For all experiments corrections pooled, diluted 2-fold with buffer A, and loaded onto a second for ionic activities (22) and liquidjunction potentials (23) were Con A-Sepharose column, which was equilibrated with 100 determined and incorporated into the analysis. Amplitude mM NaCl in buffer A. The column was washed with 100 mM histograms were measured by determining the amplitude of NaCl in buffer A and the binding protein was eluted with 0.25 all samples digitized by the computer and therefore reveal M methyl a-D-mannoside/100 mM NaCi in buffer A. The single-channel conductances and changes in open probabil- final extract (partially purified extract) was desalted by using ities (20). a PD-10 Sephadex G-25M column (Pharmacia), equilibrated in 20 mM Tris HCl, pH 7.5/5% glycerol/1% CHAPS and was RESULTS concentrated by using a Centricon 10 microconcentrator (Amicon). All procedures were performed at 4TC. Purification and Photolabeling. Previous data demon- Reconstitution and Formation of Large Liposomes. For strated that carrot cell membranes could be specifically reconstitution experiments, solubilization and purification of photolabeled by using the phenylalkylamine azido derivative the calcium channel blocker-binding protein was performed [3H]LU 49888 (13). Therefore a strategy, developed to purify according to the procedure described above without previous the calcium channel from skeletal muscle transverse tubules, treatment with [3H]LU 49888. was used for this study (24). After photolabeling, the [3H]LU Total solubilized proteins or partially purified extracts 49888-binding protein complex was purified by a combination were mixed with L-a-lecithin lipids from soybean (type II-S; of Con A-Sepharose and ion-exchange chromatographies, Sigma) dissolved in 20 mM Tris-HCl, pH 7.5/5% glycerol/1% resulting in a final purification factor of 24.6-fold and 30% CHAPS (protein-to-lipid ratio: 1 mg/100 mg). The reconsti- recovery (based on the starting soluble radioactive material) tution was performed at 40C by removing the detergent by (Table 1). This purification procedure allowed solubilization dialysis for 72 hr against three 1-liter batches of 20 mM and purification of the calcium channel blocker-binding pro- Tris HCl, pH 7.5. Subsequently, the proteoliposomes were tein from membranes which had not been photolabeled with transformed into large liposomes, suitable for patch-clamp [3H]LU 49888. The partially purified fraction contained sev- studies, by using the dehydration-rehydration technique (16, eral polypeptides (Fig. 1A, lane 1) among which only the 17). The rehydration was carried out with 20 mM Hepes-Tris, 75-kDa peptide was specifically
Recommended publications
  • A Drug Repositioning Approach Identifies Tricyclic Antidepressants As Inhibitors of Small Cell Lung Cancer and Other Neuroendocrine Tumors
    Published OnlineFirst September 26, 2013; DOI: 10.1158/2159-8290.CD-13-0183 RESEARCH ARTICLE A Drug Repositioning Approach Identifi es Tricyclic Antidepressants as Inhibitors of Small Cell Lung Cancer and Other Neuroendocrine Tumors Nadine S. Jahchan 1 , 2 , Joel T. Dudley 1 , Pawel K. Mazur 1 , 2 , Natasha Flores 1 , 2 , Dian Yang 1 , 2 , Alec Palmerton 1 , 2 , Anne-Flore Zmoos 1 , 2 , Dedeepya Vaka 1 , 2 , Kim Q.T. Tran 1 , 2 , Margaret Zhou 1 , 2 , Karolina Krasinska 3 , Jonathan W. Riess 4 , Joel W. Neal 5 , Purvesh Khatri 1 , 2 , Kwon S. Park 1 , 2 , Atul J. Butte 1 , 2 , and Julien Sage 1 , 2 Downloaded from cancerdiscovery.aacrjournals.org on September 29, 2021. © 2013 American Association for Cancer Research. Published OnlineFirst September 26, 2013; DOI: 10.1158/2159-8290.CD-13-0183 ABSTRACT Small cell lung cancer (SCLC) is an aggressive neuroendocrine subtype of lung cancer with high mortality. We used a systematic drug repositioning bioinformat- ics approach querying a large compendium of gene expression profi les to identify candidate U.S. Food and Drug Administration (FDA)–approved drugs to treat SCLC. We found that tricyclic antidepressants and related molecules potently induce apoptosis in both chemonaïve and chemoresistant SCLC cells in culture, in mouse and human SCLC tumors transplanted into immunocompromised mice, and in endog- enous tumors from a mouse model for human SCLC. The candidate drugs activate stress pathways and induce cell death in SCLC cells, at least in part by disrupting autocrine survival signals involving neurotransmitters and their G protein–coupled receptors. The candidate drugs inhibit the growth of other neuroendocrine tumors, including pancreatic neuroendocrine tumors and Merkel cell carcinoma.
    [Show full text]
  • Comparison of Electropharmacological Effects of Bepridil and Sotalol in Halothane-Anesthetized Dogs
    Circ J 2008; 72: 1003–1011 Comparison of Electropharmacological Effects of Bepridil and Sotalol in Halothane-Anesthetized Dogs Tomomichi Ishizaka, DVM*,**; Akira Takahara, PhD*; Hiroshi Iwasaki, MD*; Yoshitaka Mitsumori, MD*; Hiroaki Kise, MD*; Yuji Nakamura, MS*; Atsushi Sugiyama, MD*,** Background Bepridil is known to have a multiple ion channel-blocking property in the heart, which has been applied for the treatment of atrial fibrillation and drug-refractory ventricular tachyarrhythmias. In this study, the electro-pharmacological effects of bepridil were compared with those of dl-sotalol, a representative class III anti- arrhythmic drug, using the halothane-anesthetized canine model. Methods and Results Cardiovascular and electrophysiological variables were measured under the halothane anesthesia. Intravenous administration of bepridil (0.3mg/kg, n=4) delayed the intraventricular conduction and prolonged the ventricular effective refractory period, whereas dl-sotalol (0.3mg/kg, iv, n=4) inhibited atrioven- tricular conduction and prolonged the atrial and ventricular effective refractory period. The additional adminis- tration of 10 times the higher dose of bepridil or dl-sotalol (ie, 3mg/kg, iv, n=4 for each group) decreased blood pressure, suppressed ventricular contraction and sinus automaticity, and prolonged the atrial and ventricular effective refractory period and monophasic action potential duration, in addition to the effects of the low dose. Conclusions The electropharmacological effects of bepridil and dl-sotalol were similar,
    [Show full text]
  • Evaluation and Management of Chronic Hepatitis C Virus Infection
    EVALUATION AND MANAGEMENT OF CHRONIC HEPATITIS C VIRUS (HCV) INFECTION Federal Bureau of Prisons Clinical Guidance MAY 2017 Federal Bureau of Prisons (BOP) Clinical Guidance is made available to the public for informational purposes only. The BOP does not warrant this guidance for any other purpose, and assumes no responsibility for any injury or damage resulting from the reliance thereof. Proper medical practice necessitates that all cases are evaluated on an individual basis and that treatment decisions are patient- specific. Consult the BOP Health Management Resources Web page to determine the date of the most recent update to this document: http://www.bop.gov/resources/health_care_mngmt.jsp. Federal Bureau of Prisons Evaluation and Management of Chronic HCV Infection Clinical Guidance May 2017 WHAT’S NEW IN BOP GUIDANCE REGARDING HCV INFECTION? The major changes included in this May 2017 update to the BOP guidance on chronic HCV infection are based primarily on the April 2017 changes to the American Association for the Study of Liver Diseases (AASLD) guidelines, as follows: • The term resistance-associated substitutions (RASs) is now being used instead of resistance- associated variants (RAVs). • Anti-HBs and anti-HBc, in addition to HBsAg, are recommended for baseline testing of hepatitis B status (see LABORATORY TESTS under BASELINE EVALUATION). • Ledipasvir/sofosbuvir once daily for eight weeks is now an AASLD-recommended regimen for treatment in a subgroup of HCV-infected persons who have genotype 1a or 1b, have an HCV viral load <6 million IU/ml, and are treatment-naïve—but who are not black, are not HIV-coinfected, and do not have cirrhosis.
    [Show full text]
  • Comparison of In-Cell Immunoassay and Automated Electrophysiology for Assessment of Herg Trafficking Liability for New Drugs
    Comparison of in-cell immunoassay and automated electrophysiology for assessment of hERG trafficking liability for new drugs Yuri Kuryshev, Peter Hawryluk, Caiyun Wu, Abby Sewell, James Kramer, Carlos Obejero-Paz, Luke Armstrong, Arthur M. Brown Charles River, Cleveland, Ohio, USA IWB/PPC 1 h IWB/PPC 24 h 1.8 1.8 hERG-Lite 16 h hERG-Lite 1 h 1 3 1.6 Abstract Results 1.6 4 Summary 1.4 1.4 hERG-Lite® is an antibody-based chemiluminescent assay that identifies compounds that disrupt Voltage clamp population patch: functional assay for 1.2 1.2 trafficking or suppress expression of hERG channel protein. Electrophysiological recording from measuring relative changes in membrane surface hERG 1.0 1.0 hERG-Lite® : in-cell immunoassay for measuring relative single cell using the manual patch-clamp technique is more direct way to quantify hERG expression in 0.8 0.8 0.6 0.6 cell membrane but this method has critical limitations: low throughput and selection bias during choice channelAa levels Ab Vehicle Control Pentamidine changes in hERG channel surface levels 24 hr. 1 hr. 0.4 0.4 Fraction of Control Fraction of Control of cells for patching. Application of the automated population patch clamp technique for the hERG 1hr. 30 M/1 hr. 30 M 30 M 0.2 0.2 VC Pent. VC Pent. expression analysis provides a dramatic increase in throughput and eliminates the cell selection bias. 0.0 0.0 hERG-Lite WB* IWB/PPC We analyzed a panel of drugs (Amiodarone, Amitriptyline, Bepridil, Diphenhydramine, Dofetilide, 0.03 0.1 0.3 1 0.03 0.1 0.3 1 Amiodarone ↓ ↓ N.D.** Fluoxetine, Imipramine, Ouabaine, Pentamidine, Pimozide, Sunitinib and Verapamil) for chronic effects Pimozide, M Pimozide, M Amitriptyline ↓ ↓ ↓ on hERG channel trafficking and expression by the hERG-Lite® method and with IonWorks Barracuda IWB/PPC 1 h IWB/PPC 24 h hERG-Lite 1 h hERG-Lite 16 h (IWB), a population-based automated patch clamp platform.
    [Show full text]
  • Drug and Medication Classification Schedule
    KENTUCKY HORSE RACING COMMISSION UNIFORM DRUG, MEDICATION, AND SUBSTANCE CLASSIFICATION SCHEDULE KHRC 8-020-1 (11/2018) Class A drugs, medications, and substances are those (1) that have the highest potential to influence performance in the equine athlete, regardless of their approval by the United States Food and Drug Administration, or (2) that lack approval by the United States Food and Drug Administration but have pharmacologic effects similar to certain Class B drugs, medications, or substances that are approved by the United States Food and Drug Administration. Acecarbromal Bolasterone Cimaterol Divalproex Fluanisone Acetophenazine Boldione Citalopram Dixyrazine Fludiazepam Adinazolam Brimondine Cllibucaine Donepezil Flunitrazepam Alcuronium Bromazepam Clobazam Dopamine Fluopromazine Alfentanil Bromfenac Clocapramine Doxacurium Fluoresone Almotriptan Bromisovalum Clomethiazole Doxapram Fluoxetine Alphaprodine Bromocriptine Clomipramine Doxazosin Flupenthixol Alpidem Bromperidol Clonazepam Doxefazepam Flupirtine Alprazolam Brotizolam Clorazepate Doxepin Flurazepam Alprenolol Bufexamac Clormecaine Droperidol Fluspirilene Althesin Bupivacaine Clostebol Duloxetine Flutoprazepam Aminorex Buprenorphine Clothiapine Eletriptan Fluvoxamine Amisulpride Buspirone Clotiazepam Enalapril Formebolone Amitriptyline Bupropion Cloxazolam Enciprazine Fosinopril Amobarbital Butabartital Clozapine Endorphins Furzabol Amoxapine Butacaine Cobratoxin Enkephalins Galantamine Amperozide Butalbital Cocaine Ephedrine Gallamine Amphetamine Butanilicaine Codeine
    [Show full text]
  • Evaluation of Ruxolitinib and Pracinostat Combination As a Therapy for Patients with Myelofibrosis 2014-0445
    2014-0445 October 23, 2016 Page 1 Protocol Page EVALUATION OF RUXOLITINIB AND PRACINOSTAT COMBINATION AS A THERAPY FOR PATIENTS WITH MYELOFIBROSIS 2014-0445 Core Protocol Information Short Title Ruxolitinib and Pracinostat Combination Therapy for Patients with MF Study Chair: Srdan Verstovsek Additional Contact: Paula J. Cooley Sandra L. Rood Leukemia Protocol Review Group Department: Leukemia Phone: 713-792-7305 Unit: 428 Full Title: EVALUATION OF RUXOLITINIB AND PRACINOSTAT COMBINATION AS A THERAPY FOR PATIENTS WITH MYELOFIBROSIS Protocol Type: Standard Protocol Protocol Phase: Phase II Version Status: Terminated 06/01/2018 Version: 13 Submitted by: Sandra L. Rood--10/23/2017 2:12:37 PM OPR Action: Accepted by: Elizabeth Orozco -- 10/26/2017 1:34:18 PM Which Committee will review this protocol? The Clinical Research Committee - (CRC) 2014-0445 October 23, 2016 Page 2 Protocol Body EVALUATION OF RUXOLITINIB AND PRACINOSTAT COMBINATION AS A THERAPY FOR PATIENTS WITH MYELOFIBROSIS 1.0 HYPOTHESIS AND OBJECTIVES Hypothesis Ruxolitinib (also known as INCB018424), a JAK1/2 inhibitor, and pracinostat (a histone deacetylase inhibitor; HDACi) are effective and tolerable treatments for patients with myelofibrosis (MF). Combination of these agents in patients with MF can improve the overall clinical response to therapy without causing excessive toxicity. Objectives Primary: to determine the efficacy/clinical activity of the combination of ruxolitinib with pracinostat as therapy in patients with MF Secondary: to determine the toxicity of the combination of ruxolitinib with pracinostat as therapy in patients with MF Exploratory: to explore time to response and duration of response to explore changes in bone marrow fibrosis to explore changes in JAK2V617F (or other molecular marker) allele burden or changes in cytogenetic abnormalities 2.0 BACKGROUND AND RATIONALE 2.1 Myelofibrosis Myelofibrosis (MF) is a rare clonal proliferative disorder of a pluripotent stem cell.
    [Show full text]
  • Neuroleptics of the Diphenylbutylpiperidine Series Are Potent Calcium Channel Inhibitors
    Proc. Nati. Acad. Sci. USA Vol. 83, pp. 7513-7517, October 1986 Neurobiology Neuroleptics of the diphenylbutylpiperidine series are potent calcium channel inhibitors (fluspirilene/desmethoxverapamil/binding/voltage-clamp/skeletal muscle) JEAN-PIERRE GALIZZI, MICHEL FOSSET, GEORGES ROMEY, PIERRE LADURON*, AND MICHEL LAZDUNSKI Centre de Biochimie du Centre National de la Recherche Scientifique, Parc Valrose, 06034 Nice Cedex, France Communicated by Jean-Marie Lehn, June 5, 1986 ABSTRACT [1t4]Fluspirilene, a neuroleptic molecule of spirilene and directly demonstrate that molecules in the the diphenylbutylpiperidine series, binds to skeletal muscle DPBP series are among the most potent inhibitors of the transverse tubule membranes with a high affinity correspond- skeletal muscle Ca2+ channel. ing to a Kd of 0.11 * 0.04 nM. A 1:1 stoichiometry was found between [3H]fluspirilene binding and the binding of (-)- [3H]desmethoxyverapamil {(-)[3H]D888}, one of the most MATERIALS AND METHODS potent Ca2+ channel inhibitors. Ca2+ channel inhibitors such as D888, verapamil, gallopamil, bepridil, or diltiazem antag- Materials. (-)[3H]D888 (82 Ci/mmol; 1 Ci = 37 GBq) and onize [3H]fluspirilene binding besides antagonizing (-)[3H]- the 1,4-dihydropyridine (+)[3H]PN 200-110 (80 Ci/mmol) D888 binding. Neuroleptics, especially those of the diphenyl- were obtained from Amersham; (-)D888, verapamil, and butylpiperidine family, also antagonize both (-)[3H]D888 gallopamil were from Knoll AG (Ludwigshafen, F.R.G.); binding and [3H]fluspirilene binding. There is an excellent bepridil and the bepridil analogs 4205 {1-[(1-propynyl)- correlation between affinities found from [3H~fluspirilene bind- cyclohexyloxy]-2-(1-pyrrolidinyl)-3-[(2-methyl)propoxyjpro- ing experiments and those found from (-)[3H]D888 binding pane chlorhydrate} and 11787 [N-(4-chloro)phenylmethyl-N- experiments.
    [Show full text]
  • ( 12 ) United States Patent
    US010117881B2 (12 ) United States Patent ( 10 ) Patent No. : US 10 , 117 ,881 B2 Helson (45 ) Date of Patent: * Nov. 6 , 2018 ( 54 ) PROTECTIVE EFFECT OF DMPC , DMPG , (58 ) Field of Classification Search DMPC /DMPG , LYSOPG AND LYSOPC None AGAINST DRUGS THAT CAUSE See application file for complete search history . CHANNELOPATHIES (71 ) Applicant: SignPath Pharma Inc. , Quakertown , ( 56 ) References Cited PA ( US) U . S . PATENT DOCUMENTS (72 ) Inventor: Lawrence Helson , Quakertown , PA 4 , 812 , 312 A 3 / 1989 Lopez -Berestein et al . (US ) 5 ,023 ,087 A 6 / 1991 Yau - Young 5 ,679 ,864 A 10 / 1997 Krackov et al . ( 73 ) Assignee : Signpath Pharma, Inc. , Sandy, UT 6 , 143 , 276 A 11/ 2000 Unger (US ) 6 , 787 , 132 B1 9 /2004 Gabison et al . 6 , 946 ,475 B1 9 / 2005 Lloyd ( * ) Notice : Subject to any disclaimer, the term of this 7 ,060 ,733 B2 6 / 2006 Pandol et al . patent is extended or adjusted under 35 7 , 067 , 159 B2 6 / 2006 Katz et al. U . S . C . 154 ( b ) by 0 days. 7 , 507 , 864 B2 3 / 2009 Miller et al. 7 ,674 , 820 B2 3 / 2010 Fedida et al. This patent is subject to a terminal dis 7 , 723 , 515 B1 5 / 2010 DiMauro claimer. 7 ,871 ,609 B2 1 / 2011 Ziff et al . 7 , 968, 115 B26 / 2011 Kurzrock et al . 8 , 062 ,663 B2 11/ 2011 Wang et al. ( 21) Appl . No. : 15 /347 , 381 8 , 153 , 172 B2 4 / 2012 Antony 8 , 202, 839 B1 6 / 2012 Sung (22 ) Filed : Nov . 9 , 2016 8 , 207 ,219 B2 6 / 2012 Fedida et al .
    [Show full text]
  • Prescription Medications, Drugs, Herbs & Chemicals Associated With
    Prescription Medications, Drugs, Herbs & Chemicals Associated with Tinnitus American Tinnitus Association Prescription Medications, Drugs, Herbs & Chemicals Associated with Tinnitus All rights reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form, or by any means, without the prior written permission of the American Tinnitus Association. ©2013 American Tinnitus Association Prescription Medications, Drugs, Herbs & Chemicals Associated with Tinnitus American Tinnitus Association This document is to be utilized as a conversation tool with your health care provider and is by no means a “complete” listing. Anyone reading this list of ototoxic drugs is strongly advised NOT to discontinue taking any prescribed medication without first contacting the prescribing physician. Just because a drug is listed does not mean that you will automatically get tinnitus, or exacerbate exisiting tinnitus, if you take it. A few will, but many will not. Whether or not you eperience tinnitus after taking one of the listed drugs or herbals, or after being exposed to one of the listed chemicals, depends on many factors ‐ such as your own body chemistry, your sensitivity to drugs, the dose you take, or the length of time you take the drug. It is important to note that there may be drugs NOT listed here that could still cause tinnitus. Although this list is one of the most complete listings of drugs associated with tinnitus, no list of this kind can ever be totally complete – therefore use it as a guide and resource, but do not take it as the final word. The drug brand name is italicized and is followed by the generic drug name in bold.
    [Show full text]
  • Medications to Avoid in Long QT Syndrome
    Jackie Crawford Cardiac Inherited Disease Co-ordinator C/- Paediatric Cardiology; Level 3 Starship; Auckland City Hospital Private Bag 92024; Auckland Cardiac Inherited Disease Registry Phone: (09) 3074949 ext 23634 www.cidg.org Fax: (09) 6309877 Email: [email protected] Medications to be avoided, or requiring special caution, in people with Long QT syndrome This list includes medications which prolong the QT interval and is meant as a guide for people with Long QT syndrome, or acquired long QT interval from heart muscle disease, and their parents or guardians. It should not be seen as all inclusive. Those prescribing any medication to someone with Long QT syndrome should always check the drug specifications and contra-indications. The list has been compiled by review of publications and/or drug advice sheets provided with medications. Check also www.SADS.org and www.Torsades .org. Antibiotics Erythromycin, Clarithromycin, Gatifloxacin, levofloxacin, Moxifloxacin Sulfamethoxazole-trimethoprim (Septrin/Bactrim), Spiramycin, Pentamidine Antihistamines Terfenadine, Astemizole, Diphenhydramine, (These are particularly to be avoided (even in normal subjects) in combination with Erythromycin or grapefruit juice or the antifungals ketoconazole, miconazole, fluconazole or itraconazole) [Antihistamines that may be used safely are loratidine, cetirizine and fexofenadine, and phenergan] Appetite suppressants Fenfluramine, phentermine, Sibutramine Asthma treatments The Beta-2 agonists (e.g. Terbutaline, Salbutamol, Salmeterol) both work against
    [Show full text]
  • Johansen 1..13
    RESEARCH ARTICLE EBOLA VIRUS A screen of approved drugs and molecular probes identifies therapeutics with anti–Ebola virus activity Lisa M. Johansen,1 Lisa Evans DeWald,2 Charles J. Shoemaker,3 Benjamin G. Hoffstrom,1 Calli M. Lear-Rooney,2 Andrea Stossel,2 Elizabeth Nelson,3 Sue E. Delos,3 James A. Simmons,3 Jill M. Grenier,1 Laura T. Pierce,1 Hassan Pajouhesh,1 Joseph Lehár,1,4 Lisa E. Hensley,2 Pamela J. Glass,2 Judith M. White,3 Gene G. Olinger2*† Currently, no approved therapeutics exist to treat or prevent infections induced by Ebola viruses, and recent events have demonstrated an urgent need for rapid discovery of new treatments. Repurposing approved drugs for emerging infections remains a critical resource for potential antiviral therapies. We tested ~2600 approved drugs and molecular probes in an in vitro infection assay using the type species, Zaire ebolavirus. Selective antiviral activity was found for 80 U.S. Food and Drug Administration–approved drugs spanning multiple mech- anistic classes, including selective estrogen receptor modulators, antihistamines, calcium channel blockers, and antidepressants. Results using an in vivo murine Ebola virus infection model confirmed the protective ability of several drugs, such as bepridil and sertraline. Viral entry assays indicated that most of these antiviral drugs block a late stage of viral entry. By nature of their approved status, these drugs have the potential to be rapidly advanced to clinical settings and used as therapeutic countermeasures for Ebola virus infections. INTRODUCTION as well as drugs acting through mechanisms that would not have been Filoviruses (Ebolavirus and Marburgvirus) are responsible for acute vi- predicted (11).
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]